Navigation Links
ProUroCare Medical Inc. Announces Completion of Warrant Replacement Offering
Date:8/5/2010

EDEN PRAIRIE, Minn., Aug. 5 /PRNewswire-FirstCall/ -- ProUroCare Medical Inc. (OTC Bulletin Board: PUMD) today announced the successful completion of its tender offer to holders of certain outstanding warrants, resulting in the exercise of warrants to purchase approximately 1 million shares of common stock.  Under the offer, the terms of the warrants were temporarily modified so that holders who exercised their warrants by August 2, 2010 would receive, in addition to the shares of common stock purchased upon exercise, an equal number of three-year replacement warrants.  The replacement warrants are exercisable at $1.30 per share and may be called at ProUroCare's discretion at any time after the last sales price of its common stock equals or exceeds $4.00 per share for ten consecutive trading days.

Holders of $1.05 million of the company's debt paid for the warrant exercise by cancelling their promissory notes.  Warrants to purchase 198,312 shares of common stock were exercised for cash, resulting in gross proceeds to the company of approximately $258,000.  Cash proceeds from the offering are to be used to obtain market clearance of the ProUroScan™ system, fund manufacturing and market scale-up activities, expand intellectual property rights, form a scientific advisory panel and conduct clinical studies and for other general corporate purposes.

About ProUroCare Medical Inc.

ProUroCare Medical Inc. is a publicly traded company engaged in the business of developing innovative medical imaging products. The company's current focus is the ProUroScan prostate imaging system, which is used to document abnormalities of the prostate detected by a Digital Rectal Exam (DRE).  Based in Minneapolis, Minn., ProUroCare is quoted on the OTCBB.

Safe Harbor Statement

This news release contains certain "forward-looking" statements. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements are not guarantees of ProUroCare's future performance and involve a number of risks and uncertainties that may cause actual results to differ materially from the results discussed in these statements. Factors that might cause ProUroCare's results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the ability of ProUroCare to find adequate financing to complete the development of its products; the high level of secured and unsecured debt incurred by ProUroCare; the dependence by ProUroCare on third parties for the development and manufacture of its products; and other risks and uncertainties detailed from time to time in ProUroCare's filings with the Securities and Exchange Commission including its most recently filed Form 10-K and Form 10-Q. ProUroCare undertakes no duty to update any of these forward-looking statements.


'/>"/>
SOURCE ProUroCare Medical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ProUroCare Medical Announces Offering of Replacement Warrants in Exchange for Early Exercise of Outstanding Warrants
2. ProUroCare Medical Secures $885,000 in Financing
3. ProUroCare to Showcase Investigational Portable Platform for Its Prostate Imaging Device at AUA 2010
4. ProUroCare Medical Announces Filing of Request to Classify the Prostate Mechanical Imager ("PMI") as a Class II Device
5. ProUroCare Medical Elects Two New Directors
6. ProUroCare Medical Completes Multiple Site Clinical Study for Imaging Prostate Abnormalities
7. ProUroCare Medical Completes Clinical Trial at Second Study Site Using Digital Prostate Imaging Technology
8. ProUroCare Medical Inc. Announces Pricing of Equity Offering
9. Invivo Wins Medical Design Excellence Award for Prostate Solutions
10. Concord Medical to Report Second Quarter 2010 Financial Results on Wednesday, August 18, 2010
11. Water Street Healthcare Partners Announces New Investment in Medical Specialties Distributors, LLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... Calif. , Feb. 27, 2017  Titan ... therapeutics for the treatment of select chronic diseases ... today announced that the U.S. Food & Drug ... the ropinirole implant Investigational New Drug Application (IND) ... of the clinical study pending submission of the ...
(Date:2/28/2017)... and SAN FRANCISCO , February 27, 2017 ... Se D BioMedical ... of biotechnology assets   LOI contemplates capital infusion ... for building shareholder value   Amarantus names four new appointees ... Amarantus   SeD Biomedical Inc. (SeD ...
(Date:2/28/2017)... Feb. 27, 2017 Pulmonary drug delivery market ... from USD 36.10 billion in 2016, at a CAGR ... pulmonary route as an alternate route of drug delivery, ... increasing incidence of respiratory diseases such as COPD, asthma, ... growth during the forecast period. However, emerging markets and ...
Breaking Medicine Technology:
(Date:2/28/2017)... IL (PRWEB) , ... February 28, 2017 , ... Today, ... ten years of saving lives by empowering young women to live proactively at a ... 1 in 75 will develop ovarian cancer. Prevention and early detection can save lives-but ...
(Date:2/28/2017)... ... February 28, 2017 , ... The ... America for the scientific development, healthcare training and clinical application of medical infrared ... Session on September 16-17 in Greenville, SC at the Bon Secours St. Francis ...
(Date:2/28/2017)... CA (PRWEB) , ... February 28, 2017 , ... ... Health Coach Institute (HCI) announced a new partnership through which HCI students, ... their coaching curriculum and practices. The partnership also enables the HCI community to ...
(Date:2/28/2017)... ... February 28, 2017 , ... In 2014, Harvard researchers published a report ... from prostate cancer, the researchers found that men who had undergone a vasectomy were ... prostate cancer. Although the increased risks are small, they seem to be contradicted by ...
(Date:2/28/2017)... ... ... Las Vegas Skin and Cancer Clinic (LVSCC) is proud to announce the ... pm PST. For more than six decades, LVSCC has provided the Las Vegas community ... been renovated to provide medical and cosmetic dermatological products and services. Patients at the ...
Breaking Medicine News(10 mins):